Camrelizumab (SHR-1210)

camrelizumab · Jiangsu Hengrui Medicine Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Camrelizumab (SHR-1210), covering 2019-02-15 to 2019-02-15. Get the full timeline:

Most recent: Clinical Trial Update: Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection [Phase 2]

See pricing